Regencell Bioscience (NASDAQ:RGC) Hits New 12-Month Low – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $4.92 and last traded at $5.05, with a volume of 474147 shares. The stock had previously closed at $5.88.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Regencell Bioscience has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The firm has a 50 day simple moving average of $18.15 and a 200-day simple moving average of $24.65.

Regencell Bioscience (NASDAQ:RGC) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Regencell Bioscience

Institutional investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP acquired a new position in Regencell Bioscience in the fourth quarter valued at about $92,000. Amundi bought a new stake in Regencell Bioscience during the first quarter worth about $219,000. Hudson Bay Capital Management LP acquired a new stake in shares of Regencell Bioscience during the fourth quarter worth approximately $275,000. Bank of America Corp DE increased its holdings in shares of Regencell Bioscience by 59,113.8% during the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after buying an additional 17,143 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Regencell Bioscience in the third quarter valued at approximately $598,000. 0.13% of the stock is owned by institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.